AU708159B2 - Glucagon-like insulinotropic complexes, compositions and methods - Google Patents

Glucagon-like insulinotropic complexes, compositions and methods Download PDF

Info

Publication number
AU708159B2
AU708159B2 AU20268/95A AU2026895A AU708159B2 AU 708159 B2 AU708159 B2 AU 708159B2 AU 20268/95 A AU20268/95 A AU 20268/95A AU 2026895 A AU2026895 A AU 2026895A AU 708159 B2 AU708159 B2 AU 708159B2
Authority
AU
Australia
Prior art keywords
glp
gly
ala
histidine
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU20268/95A
Other languages
English (en)
Other versions
AU2026895A (en
Inventor
John Allison Galloway
James Arthur Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2026895A publication Critical patent/AU2026895A/en
Application granted granted Critical
Publication of AU708159B2 publication Critical patent/AU708159B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU20268/95A 1995-03-21 1995-05-24 Glucagon-like insulinotropic complexes, compositions and methods Ceased AU708159B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/407,831 US5705483A (en) 1993-12-09 1995-03-21 Glucagon-like insulinotropic peptides, compositions and methods
US407831 1995-03-21

Publications (2)

Publication Number Publication Date
AU2026895A AU2026895A (en) 1996-10-03
AU708159B2 true AU708159B2 (en) 1999-07-29

Family

ID=23613700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20268/95A Ceased AU708159B2 (en) 1995-03-21 1995-05-24 Glucagon-like insulinotropic complexes, compositions and methods

Country Status (28)

Country Link
US (7) US5705483A (enExample)
EP (2) EP0733644B1 (enExample)
JP (3) JP3502694B2 (enExample)
KR (1) KR100388583B1 (enExample)
CN (1) CN1185257C (enExample)
AT (2) ATE312119T1 (enExample)
AU (1) AU708159B2 (enExample)
BR (1) BR9503036A (enExample)
CA (1) CA2150080A1 (enExample)
CO (1) CO4650140A1 (enExample)
CZ (1) CZ292972B6 (enExample)
DE (2) DE69534678T2 (enExample)
DK (2) DK1364967T3 (enExample)
ES (2) ES2250789T3 (enExample)
FI (1) FI952536A7 (enExample)
HU (1) HUT74729A (enExample)
IL (2) IL113809A (enExample)
MY (1) MY134820A (enExample)
NO (1) NO322837B1 (enExample)
NZ (1) NZ272186A (enExample)
PE (1) PE23296A1 (enExample)
PL (1) PL182113B1 (enExample)
PT (1) PT733644E (enExample)
RU (1) RU2147588C1 (enExample)
SI (1) SI1364967T1 (enExample)
TW (1) TW389769B (enExample)
UA (1) UA44696C2 (enExample)
ZA (1) ZA954141B (enExample)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
AU4063697A (en) * 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
ATE304864T1 (de) * 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE69911975T2 (de) * 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
EP1666054A1 (en) 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1113799A4 (en) 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
PL202367B1 (pl) * 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
DE69938669D1 (de) * 1998-12-07 2008-06-19 Sod Conseils Rech Applic Analoge des glucagon ähnlichen peptides-1 (glp-1)
SI1140148T1 (sl) * 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
JP4689833B2 (ja) * 1998-12-22 2011-05-25 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１の貯蔵安定性製剤
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
US6864234B1 (en) * 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
JP4713798B2 (ja) 1999-06-29 2011-06-29 マンカインド コーポレイション ペプチドおよびタンパク質の薬学的因子の精製および安定化
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DE19940130A1 (de) * 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
DE60132723T2 (de) 2000-01-21 2009-01-29 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6448045B1 (en) 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
EP2055302B1 (en) * 2000-03-31 2014-09-10 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
KR100847615B1 (ko) * 2000-06-16 2008-07-21 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
KR100407792B1 (ko) * 2000-08-02 2003-12-01 한국생명공학연구원 인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
JP2004510716A (ja) * 2000-10-02 2004-04-08 ユーエスヴイ　リミテッド メトフォルミン含有持続性放出薬理組成物とその製造方法
KR20030096227A (ko) * 2000-10-27 2003-12-24 프로비오드룩 아게 신경 및 신경정신 질환의 치료방법
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) * 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1385549A2 (en) * 2001-03-12 2004-02-04 Novartis AG Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US7368421B2 (en) * 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
JP5562510B2 (ja) * 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
WO2003015768A2 (en) * 2001-08-16 2003-02-27 Probiodrug Ag Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US6844316B2 (en) * 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
US6911324B2 (en) * 2001-10-18 2005-06-28 The Regents Of The University Of California Induction of beta cell differentiation in human cells
MXPA04003569A (es) * 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
KR101165431B1 (ko) 2002-02-20 2012-07-12 에미스페어 테크놀로지스, 인코포레이티드 Ｇｌｐ-1 분자의 투여 방법
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
WO2004031374A2 (en) * 2002-09-18 2004-04-15 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)
WO2004029081A2 (en) 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
CA2500295A1 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
RU2234703C1 (ru) * 2002-12-18 2004-08-20 Мищенко Борис Петрович Способ количественного определения гликогемоглобина
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR20050086948A (ko) * 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
ATE455555T1 (de) * 2003-02-19 2010-02-15 Ipsen Pharma Glp-1-analoga
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
US20070167359A1 (en) * 2003-04-15 2007-07-19 Moshe Baru Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
DK2206496T3 (da) * 2003-05-05 2014-12-15 Probiodrug Ag Screening af inhibitorer af pyroglutaminsyredannelse i amyloid beta-peptid
ZA200508439B (en) * 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
ATE529126T1 (de) * 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
DK1675578T3 (da) * 2003-10-15 2013-08-26 Probiodrug Ag Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD
AU2004290862B2 (en) * 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
JP2007514752A (ja) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2007519642A (ja) * 2004-01-30 2007-07-19 ワラタ ファーマシューティカルズ， インコーポレイテッド 血糖値を調節するためのｇｌｐ−１アゴニストとガストリンとの合わせた使用
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2564031A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
WO2006024631A2 (en) * 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
JP5175103B2 (ja) * 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006097535A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
CA2611002A1 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic .beta. cell proliferation
US20070004616A1 (en) * 2005-06-30 2007-01-04 Roland Cherif-Cheikh GLP-1 pharmaceutical compositions
WO2007005738A2 (en) * 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP5167133B2 (ja) 2005-09-14 2013-03-21 マンカインド コーポレイション 結晶性微粒子表面に対する活性薬剤の親和性の増大に基づく薬物処方の方法
ATE448247T1 (de) 2005-09-22 2009-11-15 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EP1943275B1 (en) * 2005-11-01 2010-06-16 Activotec SPP Limited Insulinotropic compounds and uses thereof
GB0522295D0 (en) * 2005-11-01 2005-12-07 Activotec Spp Ltd Peptides and uses thereof
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP1976876A4 (en) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
EP2573111A1 (en) * 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
RU2448978C2 (ru) * 2006-06-23 2012-04-27 Ф.Хоффманн-Ля Рош Аг Синтез инсулинотропных пептидов
US20090325873A1 (en) * 2006-07-18 2009-12-31 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
UY30820A1 (es) * 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CN101969928B (zh) 2007-10-24 2014-05-07 曼金德公司 活性剂的递送
RU2474415C2 (ru) * 2007-10-24 2013-02-10 Маннкайнд Корпорейшн Способ предотвращения побочных эффектов glp-1
JP5473925B2 (ja) * 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
CN101918027A (zh) * 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP5421362B2 (ja) 2008-06-13 2014-02-19 マンカインド コーポレイション 薬物送達用の乾燥粉末吸入器およびシステム
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
PL3228320T3 (pl) 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
JP5514831B2 (ja) * 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
BRPI1012852A2 (pt) 2009-05-15 2018-06-19 Novartis Ag derivados de benzoxazolona como inibidores da sintase de aldoesterona
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
EP3048100A1 (en) 2009-05-28 2016-07-27 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
KR101943420B1 (ko) 2009-08-14 2019-04-17 파세비오 파마수티컬스 인코포레이티드 변형된 혈관활성 장 펩티드
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
CA3011480C (en) 2009-11-13 2021-11-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
WO2011061168A1 (en) 2009-11-17 2011-05-26 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
CA2802931C (en) 2010-05-17 2016-10-04 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
HUE036066T2 (hu) 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
EP2665470A1 (en) * 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014DN03093A (enExample) 2011-10-24 2015-05-15 Mannkind Corp
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
CN110041399B (zh) 2011-12-29 2023-12-12 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
SG11201500375PA (en) 2012-07-23 2015-02-27 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
ES2754388T3 (es) 2013-03-15 2020-04-17 Mannkind Corp Composiciones y métodos de dicetopiperazina microcristalina
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN119119235A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2015340586B2 (en) 2014-10-29 2020-04-30 Zealand Pharma A/S GIP agonist compounds and methods
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
CN105820233B (zh) * 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
RS64643B1 (sr) 2018-02-02 2023-10-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
CN113166204B (zh) 2018-11-27 2025-01-28 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN121219288A (zh) 2023-05-24 2025-12-26 诺华股份有限公司 用于治疗疾病或障碍的萘啶酮衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
EP0619322A2 (en) * 1993-04-07 1994-10-12 Pfizer Inc. Prolonged delivery of peptides
WO1995005848A1 (en) * 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347374A (en) * 1980-07-21 1982-08-31 Merck & Co., Inc. Acid addition salts of N-trityl-α-fluoromethylhistidine enantiomer derivatives
CA1341320C (en) * 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0542937A1 (en) * 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
CZ315594A3 (en) * 1992-06-15 1995-07-12 Pfizer Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
CA2137206A1 (en) * 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
EP0619322A2 (en) * 1993-04-07 1994-10-12 Pfizer Inc. Prolonged delivery of peptides
WO1995005848A1 (en) * 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1

Also Published As

Publication number Publication date
KR100388583B1 (ko) 2003-09-13
PL308783A1 (en) 1996-09-30
JP3502694B2 (ja) 2004-03-02
ATE312119T1 (de) 2005-12-15
HUT74729A (en) 1997-02-28
US6133235A (en) 2000-10-17
EP0733644A1 (en) 1996-09-25
SI1364967T1 (sl) 2006-04-30
RU95108231A (ru) 1997-03-20
US6388053B1 (en) 2002-05-14
CZ132195A3 (en) 1996-10-16
DE69532914T2 (de) 2005-03-31
US7232879B2 (en) 2007-06-19
CO4650140A1 (es) 1998-09-03
NO952034D0 (no) 1995-05-23
FI952536L (fi) 1996-09-22
DE69534678T2 (de) 2006-09-07
HU9501508D0 (en) 1995-07-28
DK1364967T3 (da) 2006-03-27
ZA954141B (en) 1996-11-22
ATE264869T1 (de) 2004-05-15
CN1131674A (zh) 1996-09-25
NO952034L (no) 1996-09-23
JP2004002480A (ja) 2004-01-08
FI952536A0 (fi) 1995-05-24
MY134820A (en) 2007-12-31
EP1364967A3 (en) 2004-01-28
TW389769B (en) 2000-05-11
AU2026895A (en) 1996-10-03
ES2218536T3 (es) 2004-11-16
PT733644E (pt) 2004-07-30
FI952536A7 (fi) 1996-09-22
DE69532914D1 (de) 2004-05-27
JPH08269097A (ja) 1996-10-15
US6703365B2 (en) 2004-03-09
CN1185257C (zh) 2005-01-19
JP2003048899A (ja) 2003-02-21
EP0733644B1 (en) 2004-04-21
DE69534678D1 (de) 2006-01-12
BR9503036A (pt) 1997-09-23
EP1364967A2 (en) 2003-11-26
IL134853A0 (en) 2001-05-20
IL113809A (en) 2000-07-26
US5705483A (en) 1998-01-06
CA2150080A1 (en) 1996-09-22
PE23296A1 (es) 1996-06-15
ES2250789T3 (es) 2006-04-16
NZ272186A (en) 1997-01-29
CZ292972B6 (cs) 2004-01-14
KR960034219A (ko) 1996-10-22
EP1364967B1 (en) 2005-12-07
PL182113B1 (pl) 2001-11-30
UA44696C2 (uk) 2002-03-15
DK0733644T3 (da) 2004-08-16
US20040127399A1 (en) 2004-07-01
IL113809A0 (en) 1995-08-31
US5977071A (en) 1999-11-02
NO322837B1 (no) 2006-12-11
US20020165342A1 (en) 2002-11-07
RU2147588C1 (ru) 2000-04-20
US6410513B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
AU708159B2 (en) Glucagon-like insulinotropic complexes, compositions and methods
EP0658568A1 (en) Glucagon-like insulinotropic peptides, compositions and methods
EP0708179B1 (en) Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5981488A (en) Glucagon-like peptide-1 analogs
EP0699686B1 (en) Biologically active fragments of glucagon-like insulinotropic peptide
EP0464022A1 (en) Insulinotropic hormone
WO1998043658A1 (en) Glucagon-like peptide-1 analogs
RS49562B (sr) Insulinotropski kompleksi, kompozicije i postupci